Overview
Veeva fiscal Q3 revenue grows 16% yr/yr, beating analyst expectations
Adjusted net income for fiscal Q3 beats consensus, reflecting strong operational performance
Adjusted operating income for fiscal Q3 exceeds analyst estimates
Outlook
Veeva expects Q4 revenue between $807 mln and $810 mln
Veeva forecasts FY revenue between $3,166 mln and $3,169 mln
Company anticipates FY non-GAAP EPS of approximately $7.93
Result Drivers
VEEVA AI ADVANCEMENT - Veeva AI's rapid progress with industry-specific AI agents is driving productivity and customer centricity in life sciences, per CEO Peter Gassner
CRM SUCCESS - Veeva Vault CRM added 23 new customers, including a significant rollout in Japan, showcasing its global capability
DEVELOPMENT CLOUD ADOPTION - Veeva Development Cloud saw adoption by several top biopharmas, advancing its position in R&D transformation
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$811.24 mln
$792.10 mln (24 Analysts)
Q3 EPS
$1.40
Q3 Adjusted Net Income
Beat
$345.10 mln
$326.60 mln (20 Analysts)
Q3 Net Income
$236.20 mln
Q3 Adjusted Operating Income
Beat
$364.90 mln
$349.80 mln (23 Analysts)
Q3 Pretax Profit
$312.79 mln
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 23 "strong buy" or "buy", 9 "hold" and 2 "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Veeva Systems Inc is $324.50, about 15.9% above its November 19 closing price of $273.00
The stock recently traded at 33 times the next 12-month earnings vs. a P/E of 36 three months ago
Press Release: ID:nPn7NjCWKa
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)